TacticScaleWhat Bio-Techne Does & How It Makes Money (TECH)
Updated October 2026 · reflects Bio-Techne's latest reported financials
Maker of life science research reagents, instruments, and diagnostic products. It sells reagents, consumables, and assay kits to research labs, drug and cell-therapy developers, and diagnostic labs, plus instruments that drive ongoing purchases of related immunoassays and consumables.
How Bio-Techne makes money
It sells reagents, consumables, and assay kits to research labs, drug and cell-therapy developers, and diagnostic labs, plus instruments that drive ongoing purchases of related immunoassays and consumables.
What Bio-Techne does
Bio-Techne, headquartered in Minneapolis and incorporated in 1976 (formerly Techne Corporation), supplies reagents, instruments, and services to the research, diagnostics, and bioprocessing markets worldwide. Its Protein Sciences segment makes biological reagents such as cytokines, growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies used in research and cell and gene therapy. It also sells automated protein analysis instruments for western blot and multiplexed ELISA workflows. The Diagnostics and Spatial Biology segment offers controls, calibrators, and assays for regulated diagnostics, tissue-based in-situ hybridization assays for spatial genomics, and genetic and oncology kits. It also sells products for genetic carrier screening and oncology diagnostics, along with process control products for hematology, blood chemistry, blood gases, and coagulation testing.
Products & services
- Cytokines, growth factors and antibodies
- Automated western blot and multiplex ELISA protein analysis instruments
- In-situ hybridization assays for spatial genomics
- Diagnostic controls, calibrators and assays
- Genetic carrier screening and oncology kits
- Hematology, blood chemistry and coagulation controls
What is Bio-Techne worth?
On an owner-earnings DCF, Bio-Techne's most-likely value is about $41 versus a recent price near $72 (43% above fair value). But TacticScale only calls a stock undervalued when the price sits below its conservative no-growth floor (~$20) with a margin of safety — so the honest verdict here is “Fairly priced — no edge.” Fair value earns its keep only at the extremes, not in the wide middle.
Price sits in the normal range — fair value isn't actionable here; it earns its keep only when price drops below the no-growth floor, or runs to roughly double the optimistic case.
Analysis, not advice. Fair value is a margin-of-safety estimate from a deterministic owner-earnings DCF, not a price target or recommendation. See the full breakdown →
Related companies
Bio-Rad Laboratories (BIO) · BioLife Solutions (BLFS) · Thermo Fisher Scientific (TMO)